NCT02810444已完成3 期
An Open-label, Prospective, Multicenter Study Investigating Clinical Efficacy, Safety, and Pharmacokinetic Properties of the Human Normal Immunoglobulin for Intravenous Administration BT595 as Replacement Therapy in Patients With Primary Immunodeficiency Disease (PID)
适应症
干预措施
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- Biotest
- 入组人数
- 81
- 试验地点
- 19
- 主要终点
- Rate of Acute Serious Bacterial Infections
研究概览
简要总结
This Phase III clinical study is to test efficacy, safety and pharmacokinetics of BT595 in treating patients with Primary Immunodeficiency (PID)
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 2 Years 至 75 Years（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Criteria for inclusion:
- •Written informed consent/assent obtained from subjects/subjects' parent(s) or legally acceptable representative indicating that they understood the purpose of, and procedures required for the study and are willing to participate in it.
- •Male or female, aged 2 through 75 years, inclusive.
- •Diagnosis of PID with impaired antibody production, ie:
- •Diagnosis of common variable immunodeficiency (CVID) as defined by the European Society for Immunodeficiencies (ESID)/Pan American Group for Immunodeficiency (PAGID) diagnostic criteria.
- •X-linked agammaglobulinaemia (XLA) as defined by ESID/PAGID diagnostic criteria.
- •Established replacement therapy with any immunoglobulin for intravenous administration (IVIg) reference preparation during the previous 6 months, including documentation of IgG trough levels.
- •Established replacement therapy with a single IVIg reference preparation for ≥3 months prior to treatment start with BT595 at a 3 week (Q3W) or 4 week (Q4W) schedule with a constant IVIg dose that did not change by ±20% of the mean dose, regular dosage intervals, and at least 1 IgG trough level of ≥5 g/L during the previous 3 months.
- •Criteria for
排除标准
- •Pregnancy or unreliable contraceptive measures or lactation period (females only).
- •Known intolerance to immunoglobulins or comparable substances (eg, vaccination reaction).
- •Known intolerance to proteins of human origin or known allergic reactions to components of the study product.
- •Participation in another clinical study within 30 days before entering the study or during the study and/or previous participation in this study.
- •Employee or direct relative of an employee of the contract research organization, the study site, or Biotest.
- •Acquired medical conditions known to cause secondary immune deficiency, such as chronic lymphatic leukemia, lymphoma, multiple myeloma, as well as protein losing enteropathies and hypoalbuminemia.
- •Other medical condition, laboratory finding, or physical examination finding that precludes participation.
- •Recent febrile illness that precludes or delays participation.
- •Active infection and receiving antibiotic therapy for the treatment of this infection at the time of screening. Note: if the subject was deemed to be a screen failure due to a nonserious active infection requiring antibiotic therapy, the subject may have been rescreened after the initial screening.
- •Therapy with systemic steroids or other immunosuppressant drugs at the time of enrollment (current daily use of corticosteroids, ie, >10 mg prednisone equivalent/day for >30 days. Intermittent corticosteroid use during the study was allowable, if medically necessary).
- •History of thrombotic events (including myocardial infarction, cerebral vascular accident [including stroke], pulmonary embolism, and deep vein thrombosis) within the 6 months before treatment start with BT595 or the presence of significant risk factors for thrombotic events.
- •Therapy with live-attenuated virus vaccines within 3 months before start of the study.
- •Selective, absolute immunoglobulin A (IgA) deficiency or known antibodies to IgA.
- •Positive diagnosis of hepatitis B or hepatitis C.
- •Positive human immunodeficiency virus (HIV) test.
- •History of drug or alcohol abuse within the 12 months before treatment start with BT
- •Inability or lacking motivation to participate in the study.
研究组 & 干预措施
BT595
Experimental
Subjects received BT595 (100 mg/mL human normal immunoglobulin) at doses between 0.2 and 0.8 g per kg body weight (bw) (2 to 8 mL/kg bw), either at a Q3W or Q4W schedule, The initial doses and dosage interval had to be consistent with the subject's prestudy IVIg treatment.
干预措施: IgG Next Generation (BT595) (Biological)
结局指标
主要结局
Rate of Acute Serious Bacterial Infections
时间窗: approx. 12 month treatment period
The primary efficacy endpoint was the rate of acute serious bacterial infections, ie, the mean number of acute serious bacterial infections \[SBIs as defined by EMA and FDA\] per subject-year.
次要结局
- Time to Resolution of Infections(approx. 12 month treatment period)
- IgG Trough Levels (Total IgG) Before Each Infusion(approx. 12 month treatment period)
- Rate of Any Infections(approx. 12 month treatment period)
- Rate of Nonserious Infections(approx. 12 month treatment period)
- Rate of Time Lost From School/Work Due to Infections(approx. 12 month treatment period)
- Antibiotic Treatment Information(approx. 12 month treatment period)
- Hospitalization / Hospitalization Due to Infection(approx. 12 month treatment period)
- Fever Episodes(approx. 12 month treatment period)
研究者
研究点 (19)
Loading locations...
相似试验
已完成
3 期
Pharmacokinetic, Efficacy and Safety of BT524 in Patients With Congenital Fibrinogen DeficiencyCongenital AfibrinogenemiaCongenital HypofibrinogenemiaNCT02065882Biotest67
已完成
3 期
This Clinical Study is to Test Efficacy and Safety of BT595 in Chronic Primary Immune Thrombocytopenia (ITP)Immune ThrombocytopeniaNCT02859909Biotest34
已完成
3 期
Safety and Efficacy Study of 4975 in Patients Undergoing Total Knee ReplacementTotal Knee Arthroplasty (Replacement)NCT00681356Anesiva, Inc.214
已完成
3 期
Study of Subcutaneous Immunoglobulin in Patients With PID Requiring IgG Replacement TherapyPrimary Immune DeficiencyNCT00419341CSL Behring49
终止
1 期
A Phase I/II Study of BMN053 in Subjects With Duchenne Muscular Dystrophy (DMD)Duchenne Muscular DystrophyNCT01957059BioMarin Pharmaceutical9